

# Alida Benfante

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6515330/publications.pdf>

Version: 2024-02-01

55  
papers

597  
citations

623188

14  
h-index

713013

21  
g-index

56  
all docs

56  
docs citations

56  
times ranked

883  
citing authors

#	ARTICLE	IF	CITATIONS
1	Asthma in the elderly: a different disease?. <i>Breathe</i> , 2016, 12, 18-28.	0.6	57
2	Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 63-67.	1.1	40
3	Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 163-173.	1.5	39
4	Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4371-4380.e4.	2.0	37
5	Lung penetration and patient adherence considerations in the management of asthma: role of extra fine formulations. <i>Journal of Asthma and Allergy</i> , 2013, 6, 11.	1.5	35
6	Serum low density lipoprotein subclasses in Asthma. <i>Respiratory Medicine</i> , 2013, 107, 1866-1872.	1.3	29
7	Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. <i>Patient Related Outcome Measures</i> , 2014, 5, 153.	0.7	25
8	Effectiveness of benralizumab in severe eosinophilic asthma: Distinct subphenotypes of response identified by cluster analysis. <i>Clinical and Experimental Allergy</i> , 2022, 52, 312-323.	1.4	19
9	Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients. <i>Clinical Interventions in Aging</i> , 2013, 8, 1329.	1.3	17
10	Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. <i>Monaldi Archives for Chest Disease</i> , 2018, 88, 886.	0.3	17
11	Urinary Incontinence in Chronic Obstructive Pulmonary Disease: A Common Co-morbidity or a Typical Adverse Effect?. <i>Drugs and Aging</i> , 2019, 36, 799-806.	1.3	17
12	The prevalence of sleep impairments and predictors of sleep quality among patients with asthma. <i>Journal of Asthma</i> , 2021, 58, 481-487.	0.9	17
13	Asthmatics with high levels of serum surfactant protein D have more severe disease. <i>European Respiratory Journal</i> , 2016, 47, 1864-1867.	3.1	16
14	Asthma in the older adult: presentation, considerations and clinical management. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1297-1308.	1.3	15
15	Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients. <i>Drugs and Aging</i> , 2020, 37, 11-18.	1.3	13
16	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661988812.	1.0	12
17	Challenges in the pharmacological treatment of geriatric asthma. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 917-926.	1.3	11
18	Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 83-87.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Are biological drugs effective and safe in older severe asthmatics?. Expert Opinion on Drug Safety, 2019, 18, 369-380.	1.0	11
20	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. World Allergy Organization Journal, 2019, 12, 100081.	1.6	11
21	Sleep Disturbances in COPD are Associated with Heterogeneity of Airway Obstruction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 350-354.	0.7	10
22	Exhaled nitric oxide is associated with cyclic changes in sexual hormones. Pulmonary Pharmacology and Therapeutics, 2013, 26, 644-648.	1.1	9
23	Early Lung Function Abnormalities in Acromegaly. Lung, 2015, 193, 393-399.	1.4	9
24	Prevalence of Arterial Hypertension and Characteristics of Nocturnal Blood Pressure Profile of Asthma Patients According to Therapy and Severity of the Disease: The BADA Study. International Journal of Environmental Research and Public Health, 2020, 17, 6925.	1.2	9
25	Severe asthma and COVID-19: lessons from the first wave. Journal of Asthma, 2020, , 1-7.	0.9	9
26	Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis. Minerva Medica, 2018, 109, 71-78.	0.3	9
27	Airway Distensibility by HRCT in Asthmatics and COPD with Comparable Airway Obstruction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 560-566.	0.7	8
28	Dynamic hyperinflation during the 6-min walk test in severely asthmatic subjects. ERJ Open Research, 2018, 4, 00143-2017.	1.1	8
29	Severe asthma at COVID-19 time: what is new on biologic therapies. Minerva Medica, 2021, 112, 114-117.	0.3	8
30	The anti-inflammatory properties of tiotropium. Lancet Respiratory Medicine, the, 2018, 6, e37.	5.2	7
31	How Effective and Safe Is Bronchial Thermoplasty in "Real Life" Asthmatics Compared to Those Enrolled in Randomized Clinical Trials?. BioMed Research International, 2016, 2016, 1-3.	0.9	6
32	The geriatric asthma: pitfalls and challenges. Asthma Research and Practice, 2016, 2, 2.	1.2	6
33	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of Clinical Medicine, 2020, 9, 2397.	1.0	6
34	Pharmacological Management of Elderly Patients with Asthma"Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?. Drugs and Aging, 2016, 33, 375-385.	1.3	5
35	The use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics. Therapeutics and Clinical Risk Management, 2016, Volume 12, 1553-1562.	0.9	4
36	Serum Surfactant Protein D as a Marker of Asthma Severity. Chest, 2016, 150, 473-474.	0.4	4

#	ARTICLE	IF	CITATIONS
37	How to unveil chronic respiratory diseases in clinical practice? A model of alliance between general practitioners and pulmonologists. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 44, 106-110.	1.1	4
38	Management of suspected COVID-19 patients in a low prevalence region. <i>Chronic Respiratory Disease</i> , 2020, 17, 147997312096184.	1.0	4
39	Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: Tips for facing the second wave. <i>Pulmonary Pharmacology and Therapeutics</i> , 2022, 73-74, 102083.	1.1	4
40	The Arg/Arg polymorphism of the ADRB2 is associated with the severity of allergic asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 1251-1252.	2.0	3
41	Serum lipoproteins are not associated with the severity of asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 57-61.	1.1	3
42	The potential role of SP-D as an early biomarker of severity of asthma. <i>Journal of Breath Research</i> , 2021, 15, 041001.	1.5	3
43	Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma?. <i>Journal of Asthma</i> , 2022, 59, 370-377.	0.9	2
44	The impact of SARS-COV2 pandemic on the management of IPF patients: Our narrative experience. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102038.	1.1	2
45	Comparison between Suspected and Confirmed COVID-19 Respiratory Patients: What Is beyond the PCR Test. <i>Journal of Clinical Medicine</i> , 2022, 11, 2993.	1.0	2
46	Arterial stiffness in symptomatic smokers with normal lung function. <i>ERJ Open Research</i> , 2017, 3, 00037-2017.	1.1	1
47	Transient asymptomatic bradycardia and Remdesivir in COVID-19 patients. <i>Minerva Medica</i> , 2022, , .	0.3	1
48	A 79-year-old-man with SARS-CoV-2 pneumonia and unusual pulmonary co-infection. <i>Minerva Respiratory Medicine</i> , 2022, 61, .	0.1	1
49	PREVALENCE OF ARTERIAL HYPERTENSION AND CHARACTERISTICS OF NOCTURNAL BLOOD PRESSURE PROFILE OF ASTHMA PATIENTS ACCORDING TO THERAPY AND SEVERITY OF THE DISEASE: THE BADA STUDY. <i>Journal of Hypertension</i> , 2021, 39, e136.	0.3	0
50	The asthma-COPD overlap syndrome (ACOS): hype or reality?. <i>Shortness of Breath</i> , 0, , .	0.0	0
51	Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis. , 2016, , .		0
52	OSACO: an observational study in asthma-COPD overlap syndrome (ACOS). , 2017, , .		0
53	Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics. , 2019, , .		0
54	Effects of anti-IL-5 receptor alpha in an ex vivo 3D model of COPD. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Fever and dyspnoea in a tracheostomised patient. <i>Breathe</i> , 2020, 16, 200115.	0.6	0